Bristol Myers Squibb Expands Opdivo Approvals for Classical Hodgkin Lymphoma

Event summary

  • Bristol Myers Squibb's Opdivo (nivolumab) received expanded U.S. and EU approvals for classical Hodgkin lymphoma (cHL) indications.
  • The FDA approved Opdivo in combination with AVD for previously untreated Stage III or IV cHL in patients aged 12 and older.
  • The European Commission approved Opdivo in combination with brentuximab vedotin for relapsed or refractory cHL in patients aged 5 to 30.
  • The approvals are based on the Phase 3 SWOG 1826 and Phase 2 CheckMate -744 studies.
  • Opdivo demonstrated a 58% reduction in the risk of disease progression or death in the SWOG 1826 study.

The big picture

Bristol Myers Squibb's expanded approvals for Opdivo in classical Hodgkin lymphoma represent a strategic shift towards immunotherapy-based combination treatments. The approvals underscore the company's commitment to advancing cancer care through innovative scientific approaches. These milestones are part of a broader industry trend towards personalized medicine and the use of immune checkpoint inhibitors to improve patient outcomes in hematologic malignancies.

What we're watching

Market Expansion
How the expanded approvals will impact Bristol Myers Squibb's market share in the cHL treatment space.
Clinical Efficacy
Whether the positive trial results will translate into long-term patient benefits and sustained market demand.
Regulatory Dynamics
The pace at which additional regulatory approvals for Opdivo combinations may be secured in other regions.